Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin as adjunctive treatment for challenging behaviors in children with autism spectrum disorder and intellectual disability (OT-DEFI)
2024-516306-28-00Phase 3Suspended
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of oxytocin in Autism Spectrum Disorder (ASD) and intellectual disability (ID), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Feasibility of oxytocin administration protocol. Started Sep 2024; status: suspended.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)intellectual disability (ID)
Beyond the preview
Go deeper on 2024-516306-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516306-28-00.